Recombinant grass pollen allergy vaccine ameliorates symptoms of grass pollen-induced hayfever in a double-blind, placebo-controlled multicenter field phase IIb trial

First vaccine in the world developed against grass pollen allergy

(Vienna, 18 January 2018) Viennese product: collaboration between MedUni Vienna and Biomay AG
Around 400 million people world-wide suffer in some form or other from a grass pollen allergy (rhinitis) – with the usual symptoms such as a runny nose, cough and severe breathing problems. In collaboration with the Viennese firm Biomay AG, MedUni Vienna researchers at the Institute of Pathophysiology and Allergy Research have now shown in a Phase II-b study with 180 patients in 11 European centres, that four injections of the synthetically manufactured vaccine BM32 in the first year and a top-up in the second year of treatment relieve the sufferers' symptoms by at least 25%.”


Related links: